CUL1

CUL1

A gene on chromosome 7q36.1 that encodes cullin-1, a component of the multiple cullin-RING-based SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. Cullin-1 is thought to contribute to catalysis by positioning the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex depends on the neddylation of the cullin subunit, and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1.
Mentioned in ?
References in periodicals archive ?
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
The design of a multiple drug combination for treating stage 1 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, CALR, PDIA3, DNAJB11, HSPA5, RPN1, CUL1, HSP90B1, KPNA2, PSMD12, ECT2, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes UBC, JUN, RARRES3, and FOS; and suppressing the drug's effect on the nondifferentially expressed genes BAG6, HUWE1, PAAF1, PSMD10, FAF2, PCYT1A, and PSMD10.
Stage 1 bladder Stage 4 bladder cancer cancer The highly expressed ADRM1, COPS5, PSMD8, ADRM1, COPS5, PSMD8, genes for potential SUMO2, CALR, PDIA3, SUMO2, RNF126, CALR, inhibition strategy DNAJB11, HSPA5, RPN1, PDIA3, DNAJB11, of multiple drug CUL1, HSP90B1, KPNA2, HSPA5, RPN1, design PSMD12, ECT2, TK1, HSP90AA1, HSPA1B, TUBA1C, HN1, and ENO1 METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1 The suppressed genes UBC, JUN, RARRES3, BCL3, FOS, UBC, and for potential and FOS GTF2A1 activation strategy of multiple drug design The BAG6, HUWE1, PAAF1, BAG6, HUWE1, PAAF1, nondifferentially PSMD10, FAF2, PCYT1A, PSMD10, FAF2, PCYT1A, expressed genes to and PSMD10 and PSMD10 avoid side-effect of multiple drug design The potential multiple drug combination